Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma

Abstract

Pixantrone (Pixuvri®) is an aza-anthracenedione with a novel mode of action that is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL). In the randomized, open-label, multinational, phase 3 PIX301 trial in patients with multiply relapsed or refractory aggressive NHL, the complete response (CR) plus unconfirmed CR (uCR) rate at the end of treatment (primary endpoint) was significantly higher with intravenous pixantrone monotherapy than with a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine). Post hoc analysis also demonstrated a significantly higher CR/uCR rate in the subgroup of patients with centrally confirmed aggressive B-cell NHL who were receiving pixantrone versus a comparator agent as third- or fourth-line therapy. Pixantrone was generally well tolerated in PIX301, with a manageable adverse event profile. In conclusion, pixantrone is a useful option in patients with multiply relapsed or refractory aggressive B-cell NHL. Further results examining the use of pixantrone in combination with rituximab in patients previously treated with rituximab-containing regimens are awaited with interest.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24(3):561–76.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Belada D, Georgiev P, Dakhil S, et al. Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncol. 2016;12(15):1759–68.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol. 2016;33(8):84.

    Article  PubMed  Google Scholar 

  4. 4.

    Zinzani PL, Corradini P, Martelli M, et al. Critical concepts, practice recommendations and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES. GITMO consensus paper. Eur J Haematol. 2016. doi:10.1111/ejh.12768.

    PubMed  Google Scholar 

  5. 5.

    Volpetti S, Zaja F, Fanin R. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther. 2014;7:865–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    European Medicines Agency. Pixuvri (pixantrone): EU summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 10 Oct 2016.

  7. 7.

    Pettengell R, Kaur J. Pixantrone dimaleate for treating non-Hodgkin’s lymphoma. Exp Opin Orphan Drugs. 2015;3(6):747–57.

    CAS  Article  Google Scholar 

  8. 8.

    Menna P, Salvatorelli E, Minotti G. Rethinking drugs from chemistry to therapeutic opportunities: pixantrone beyond anthracyclines. Chem Res Toxicol. 2016;29(8):1270–8.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344(2):467–78.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Evison BJ, Mansour OC, Menta E, et al. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucl Acids Res. 2007;35(11):3581–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Hasinoff BB, Wu X, Patel D, et al. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase IIα isoform. J Pharmacol Exp Ther. 2016;356(2):397–409.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Beeharry N, Di Rora AGL, Smith MR, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397–406.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori. 2001;87(6):407–16.

    CAS  PubMed  Google Scholar 

  14. 14.

    Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007;25(3):187–95.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Longo M, Della Torre P, Allievi C, et al. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice: comparative study with doxorubicin. Reprod Toxicol. 2014;46:20–30.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Faivre S, Raymond E, Boige V, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res. 2001;7(1):43–50.

    CAS  PubMed  Google Scholar 

  17. 17.

    Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma. Ann Oncol. 2001;12(5):661–7.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Lim S-T, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48(2):374–80.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer. 2000;36(18):2353–9.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica. 2003;88(8):888–94.

    CAS  PubMed  Google Scholar 

  21. 21.

    Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696–706.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.

    CAS  PubMed  Google Scholar 

  23. 23.

    Pettengell R, Sebban C, Zinzani PL, et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016;174(5):692–9.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    European Medicines Agency. Pixuvri (pixantrone): CHMP assessment report. 2012. http://www.ema.europa.eu/. Accessed 10 Oct 2016.

  25. 25.

    National Institute for Health and Care Excellence. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma. 2014. https://www.nice.org.uk/Guidance/TA306. Accessed 10 Oct 2016.

  26. 26.

    Péan E, Flores B, Hudson I, et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2013;18(5):625–33.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Beaven AW, Rizzieri D. Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clin Invest. 2012;2(1):49–58.

    CAS  Article  Google Scholar 

  29. 29.

    Eyre TA, Linton KM, Rohman P, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. Br J Haematol. 2016;173(6):896–904.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Muszbek N, Kadambi A, Lanitis T, et al. The cost-effectiveness of pixantrone for third/fourth-line treatment of aggressive non-Hodgkin’s lymphoma. Clin Ther. 2016;38(3):503–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of pixantrone was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gillian M. Keating.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Gillian Keating is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: C. Gisselbrecht, Institut d’Hématologie Hopital Saint Louis, Paris, France; R. Herbrecht, Department of Oncology and Hematology, Hôpital de Hautepierre and Université de Strasbourg, Strasbourg, France; P.L. Zinzani, Institute of Hematology “Seragnoli”, University of Bologna, Bologna, Italy.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma. Drugs 76, 1579–1586 (2016). https://doi.org/10.1007/s40265-016-0650-8

Download citation

Keywords

  • Left Ventricular Ejection Fraction
  • Mitoxantrone
  • Overall Response Rate
  • Repaglinide
  • International Prognostic Index